Neoaska Pharma Profile
Key Indicators
- Authorised Capital ₹ 150.00 Cr
as on 04-07-2024
- Paid Up Capital ₹ 23.12 Cr
as on 04-07-2024
- Company Age 7 Year, 2 Months
- Last Filing with ROC 31 Mar 2019
- Satisfied Charges ₹ 18.96 Cr
as on 04-07-2024
- Revenue %
(FY 2019)
- Profit 17240.00%
(FY 2019)
- Ebitda -20060.00%
(FY 2019)
- Net Worth 1834440.00%
(FY 2019)
- Total Assets 924.26%
(FY 2019)
About Neoaska Pharma
The Corporate was formerly known as Omnicare Aska Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2019. It's a company limited by shares with an authorized capital of Rs 150.00 Cr and a paid-up capital of Rs 23.12 Cr.
The company has closed loans amounting to ₹18.96 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Nagaraja Yancharla and Sharan Alla serve as directors at the Company.
- CIN/LLPIN
U74999TG2017PTC119969
- Company No.
119969
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Oct 2017
- Date of AGM
04 Sep 2019
- Date of Balance Sheet
31 Mar 2019
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Neoaska Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nagaraja Yancharla  | Director | 13-Jul-2023 | Current |
| Sharan Alla | Director | 13-Jul-2023 | Current |
Financial Performance and Corporate Structure Insights of Neoaska Pharma.
Neoaska Pharma Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 17240% increase in profit. The company's net worth Soared by an impressive increase of 1834440%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neoaska Pharma?
In 2019, Neoaska Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ardha Holding Private LimitedActive 14 years 1 monthNagaraja Yancharla and Sharan Alla are mutual person
- Madhya Pradesh Waste Management Private LimitedActive 13 years 11 months
Nagaraja Yancharla and Sharan Alla are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Oct 2019 | ₹18.96 Cr | Satisfied |
How Many Employees Work at Neoaska Pharma?
Neoaska Pharma has a workforce of 30 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neoaska Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neoaska Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
